reports
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos Initiates wind-down of cell Tx after conclusion of works cou...
Galapagos announced that the previously reported works council consultation process regarding the wind-down of cell therapy activities has now been completed and its Board of Directors has decided to initiate the wind-down of the company's cell therapy activities. This decision follows a strategic review and sale process in 2025 where no viable offers emerged. We believe the wind-down creates clarity and, once completed, will allow management to move forward with their plan of building a new pip...
Fagron announces the completion of Purifarma
Fagron announces the completion of Purifarma Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET Fagron announces the completion of Purifarma Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of Purifarma in Brazil, an important milestone in executing our disciplined M&A strategy. The completion of this transaction follows competition clearance by CADE, the Brazilian antitrust authority, last October, and will strengthen Fagron’s scalable, high-quality platform, in line ...
Fagron kondigt de afronding van de overname van Purifarma aan
Fagron kondigt de afronding van de overname van Purifarma aan Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 6 januari 2026 – 7:00 AM CET Fagron kondigt de afronding van de overname van Purifarma aan Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om de afronding van de overname van Purifarma in Brazilië aan te kondigen. Een belangrijke mijlpaal in de uitvoering van onze gedisciplineerde M&A-strategie. De afronding van Purifarma volgt op de goedkeuring van CADE, de Braziliaanse mededingingsautoriteit, in oktober vo...
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Thera...
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company’s cell therapy activities. On , Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an exploration of potential divestment...
Galapagos kondigt besluit van de Raad van Bestuur aan om de afbouw van...
Galapagos kondigt besluit van de Raad van Bestuur aan om de afbouw van de celtherapieactiviteiten te starten Mechelen, België; 5 januari 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag bekendgemaakt dat de overlegprocedures met de ondernemingsraden met betrekking tot de afbouw van de celtherapieactiviteiten zijn afgerond en dat de Raad van Bestuur heeft besloten de afbouw van de celtherapieactiviteiten van het bedrijf te starten. Op kondigde Galapagos aan dat het van plan was zijn celtherapieactiviteiten af te bouwen na een uitgebreide strategische evaluatie en ee...
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Robert Jan Vos
- Usama Tariq
- Jacob Mekhael
Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE
Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but fi...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
Fagron versnelt globale expansie met twee strategische overnames en ve...
Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 19 december 2025 – 7:00 AM CET Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om twee strategische overnames aan te kondigen. Deze overnames helpen om onze globale aanwezigheid verder te versterken en capaciteiten te diversifiëren...
Fagron accelerates global expansion with two strategic acquisitions an...
Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Fagron, the leading global player in pharmaceutical compounding, is pleased to announce two strategic acquisitions that further strengthen its global footprint and diversify its capabilities. These transactions include Amber Compounding Pharmacy, a...
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies ...
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile ...
Galapagos maakt topline resultaten bekend van twee fase 3-enabling stu...
Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes GLPG3667 bereikte het primaire eindpunt in de dermatomyositis-studie en toonde een statistisch significant klinisch voordeel en betekenisvolle verbeteringen aan op secundaire eindpunten van ziekteactiviteit in vergelijking met placebo In de studie naar systemische lupus erythematodes leverde GLPG3667 numerieke verbeteringen op voor verschillende secundaire eindpunten in vergelijking met placebo, maar bereikte het geen statisti...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Mathijs Geerts Danau
Sequana Medical New DSR patent improves value of program
Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.
- ING Helpdesk
EUR 400 million share buyback completed
EUR 400 million share buyback completed Schiphol, December 16, 2025 - Aegon announces today the successful completion of its share buyback program, which initially began on July 1, 2025, as a EUR 200 million initiative and was later expanded, on August 25, 2025, by an additional EUR 200 million, bringing the total to EUR 400 million. Between July 1, 2025, and December 15, 2025, 61,197,437 common shares were repurchased for a total amount of EUR 400 million at an average price of EUR 6.4772 per share. Aegon will cancel the repurchased shares in December 2025. For further details, visit our...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
Aegon Capital Markets Day 2025 – The Next Frontier
Aegon Capital Markets Day 2025 – The Next Frontier Strategic highlights: Aegon announces ambition to become a leading US life insurance and retirement group Aegon to move its head office and legal seat to the US and be renamed Transamerica Inc. at completion of transition, which Aegon aims to conclude by January 1, 2028Aegon Asset Management to focus on growing third-party revenues and improving efficiencyContinued focus on profitable growth in Aegon’s International business Strategic review of Aegon UK, evaluating all options, including divestment Financial highlights: Achieving all fi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.